Back
Kymera Therapeutics Quote, Financials, Valuation and Earnings
U.S. Government Report Alert Tuesday
Discover the Secret Loophole
Buy
78
KYMR
Kymera Therapeutics
Last Price:
50.04
Seasonality Move:
52.76%
7 Day Trial
ALL ACCESS PASS
$
7
The Mysterious VC Firm Behind Nvidia's Secret Weapon
Details Here!Kymera Therapeutics Price Quote
$50.04
-1.79 (-3.45%)
(Updated: November 12, 2024 at 5:55 PM ET)
Kymera Therapeutics Key Stats
Buy
78
Kymera Therapeutics (KYMR)
is a Buy
Day range:
$51.45 - $53.23
52-week range:
$13.96 - $53.27
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
41.21
P/B ratio:
3.76%
Volume:
392.4K
Avg. volume:
381.7K
1-year change:
256.96%
Market cap:
$3.4B
Revenue:
$78.6M
EPS:
$-2.34
How Much Does Kymera Therapeutics Make?
-
How Much Are Kymera Therapeutics's Sales Annually?
KYMR Revenues are $78.6M -
How Much Profit Does Kymera Therapeutics's Make A Year?
KYMR net income is -$147M
Is Kymera Therapeutics Growing As A Company?
-
What Is Kymera Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.21% -
What Is Kymera Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Kymera Therapeutics Stock Price Performance
-
Did Kymera Therapeutics Stock Go Up Last Month?
Kymera Therapeutics share price went up by 15.13% last month -
Did KYMR's Share Price Rise Over The Last Year?
KYMR share price rose by 256.96% over the past 1 year
What Is Kymera Therapeutics 52-Week High & Low?
-
What Is Kymera Therapeutics’s 52-Week High Share Price?
Kymera Therapeutics has traded as high as $53.27 over the past 52 weeks -
What Is Kymera Therapeutics’s 52-Week Low Share Price?
Kymera Therapeutics has traded as low as $13.96 over the past 52 weeks
Kymera Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Kymera Therapeutics?
-
How Much Debt Does Kymera Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Kymera Therapeutics Have?
Cash and short term investments quarterly total is $550M -
What Is Kymera Therapeutics’s Book Value Per Share?
Book value per share is 13.79
Is Kymera Therapeutics Cash Flow Positive?
-
What Is KYMR Cash Flow From Operations?
Cash flow from operations (TTM) is -$124.7M -
What Is Kymera Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $608M -
What Is Kymera Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$453.7M
Kymera Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
KYMR return on invested capital is -27.19% -
What Is Kymera Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -21.71% -
What Is KYMR Return On Equity?
ROE is a measure of profitability and is -27.19%
Kymera Therapeutics Earnings Date & Stock Price
-
What Is Kymera Therapeutics's Stock Price Today?
A single share of KYMR can be purchased today for 51.83 -
What Is Kymera Therapeutics’s Stock Symbol?
Kymera Therapeutics trades on the nasdaq under the ticker symbol: KYMR -
When Is Kymera Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Kymera Therapeutics is scheduled on February 21, 2025 -
When Is KYMR's next ex-dividend date?
Kymera Therapeutics's next ex-dividend date is November 13, 2024 -
How To Buy Kymera Therapeutics Stock?
You can buy Kymera Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Kymera Therapeutics Competitors
-
Who Are Kymera Therapeutics's Competitors?
Below is a list of companies who compete with Kymera Therapeutics or are related in some way:
Kymera Therapeutics Dividend Yield
-
What Is KYMR Dividend Yield?
Kymera Therapeutics’s dividend yield currently is 0% -
What Is Kymera Therapeutics’s Payout Ratio?
Kymera Therapeutics’s payout ratio is 0% -
When Did Kymera Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 13, 2024 -
What Is Kymera Therapeutics’s Dividend Per Share?
Kymera Therapeutics pays a dividend of $0.00 per share
Kymera Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 2.93% |
| Revenue: | -20.88% | -63.81% |
Analyst Recommendations
| Buy Recommendations: | 10 |
|---|---|
| Hold Recommendations: | 4 |
| Sell Recommendations: | 0 |
| Price Target: | 57.31 |
| Upside from Last Price: | 10.58% |